Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  B.R.A.I.N. Biotechnology Research and Information Network AG    BNN   DE0005203947

B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG

(BNN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector news

B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG achieves solid growth in the first half of the 2019/20 financial year

share with twitter share with LinkedIn share with facebook
05/29/2020 | 02:35am EDT

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Half Year Results
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG achieves solid growth in the first half of the 2019/20 financial year

29.05.2020 / 08:30
The issuer is solely responsible for the content of this announcement.


BRAIN AG achieves solid growth in the first half of the 2019/20 financial year

  • Strong growth in the BioScience segment
  • No significant Covid-19 effects


Zwingenberg, Germany
29 May 2020

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG, ISIN DE0005203947 / WKN 520394) today published its results for the first half of the 2019/20 financial year. Accordingly, the BRAIN Group generated consolidated revenues of ? 19.9 million in the reporting period from October 1, 2019 to March 31, 2020, compared to ? 18.5 million in the same period last year. This represents a growth rate of 7.6%.

Organically, i.e. on a like for like basis without Monteil Cosmetics International GmbH, whose shares were sold in June of the previous year, revenues increased by 14.1%. Total operating performance also increased by ? 0.4 million (1.9%) from ? 19.8 million to ? 20.2 million compared to the same period of the previous year. In organic terms, total operating performance increased by ? 1.4 million or 7.5% from ? 18.8 million to ? 20.2 million.

Group EBITDA improved by 50.5% from ? -1.8 million in the previous year to ? -0.9 million in the first six months of the 2019/20 financial year.

Development of the "BioScience" Segment

The "BioScience" segment, which mainly comprises the R&D project business, generated revenues of ? 6.8 million in the reporting period. Revenues were thus 31.9% higher than in the prior-year period. This increase is attributable to a larger business volume with existing customers and to the signing of new contracts for "tailor made solutions" projects.

EBITDA improved from ? -3.2 million to ? -2.4 million, mainly due to higher revenues and improved cost of materials, personnel expenses, and other expense ratios in the BioScience segment.

Development of the "BioIndustrial" segment

Revenues in the "BioIndustrial" segment fell slightly by 1.8% from ? 13.3 million to ? 13.1 million in the reporting period. This segment represents the product business of the BRAIN Group. Organically, i.e. without taking into account the disposal of shares in Monteil Cosmetics International GmbH, revenues increased by ? 0.8 million or 6.5% from ? 12.3 million to ? 13.1 million. The total operating performance decreased by 6.0% from ? 13.7 million to ? 12.8 million. Organically, the total operating performance increased by ? 0.2 million (1.7%) from ? 12.6 million to ? 12.8 million. EBITDA increased by 8.6% from ? 1.4 million to ? 1.5 million. Despite ramp-up costs for the start-up of new production facilities in Cardiff (UK) and Büttelborn, the EBITDA margin increased from 10.6% to 11.7%.

Manfred Bender, CFO of BRAIN AG, states: "I am very proud of our BRAIN Group's employees, who have managed to successfully develop our operating business during the difficult times of the pandemic outbreak".

Little impact from Corona pandemic

Brain AG has early and consistently implemented successful protective measures to prevent Covid-19-related absences from work. There were also no serious supply bottlenecks. Despite the forecasted significantly negative effects of the Corona pandemic on global economic growth, BRAIN AG is confident that it will be able to continue its significant growth within the forecasted range.

Adriaan Moelker, CEO of BRAIN AG, says: "At BRAIN, the long-term R&D project business plays an important role and we generate a substantial part of our revenues from long-term deals. This is a benefit to us in the current Corona crisis. The industries and challenges for which we develop and sell biotech products and solutions, most notably the food industry, also appear to be less affected by the corona crisis. In addition, our solutions for more sustainable products and industrial processes are gaining importance. On the journey to sustainability and the bio-economy, many industrial companies are looking for innovative technologies so that they can make their contribution to the UN goals, the SDGs".

Key financials (first six months of the financial year 2019/20)

(in EUR million) 6M 6M
  2019/20 2018/19
Revenues 19.9 18.5
BioScience 6.8 5.2
BioIndustrial 13.1 13.3
Total operating performance1 20.2 19.8
Adjusted EBITDA2 -0.7 -1.7
EBITDA -0.9 -1.8
Operating cash flow -4.1 -2.9
     
  31.03.2020 30.09.2019
Cash & cash equivalents 6.4 15.2

1 Revenues + change in inventories + other income including R&D grants.
2 The reconciliation from adjusted to unadjusted EBITDA can be found in the quarterly statement for the period ended 31 March 2020.

Additional information

BRAIN AG 6M-Report 2019/20:
https://www.brain-biotech.com/investors/financial-publications/

Financial calendar
www.brain-biotech.com/investors/financial-calendar

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the "Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business. Further information is available at www.brain-biotech.com.

B.R.A.I.N.
Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg
Germany
www.brain-biotech.com

Contact Investor Relations
Michael Schneiders
Head of Investor Relations
Phone: +49-(0)-6251-9331-86
Email: mis@brain-biotech.com

Media Contact
Dr. Stephanie Konle
Managing Associate Corporate Communications
Phone: +49-(0)-6251-9331-70
Email: stk@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.
 

Follow BRAIN AG on Twitter (Twitter@BRAINbiotech) and LinkedIn (@BRAIN AG)



29.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: ir@brain-biotech.com
Internet: www.brain-biotech.com
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1058289

 
End of News DGAP News Service

1058289  29.05.2020 

fncls.ssp?fn=show_t_gif&application_id=1058289&application_name=news&site_id=zonebourse

© EQS 2020
share with twitter share with LinkedIn share with facebook
All news about B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG
09/25B R A I N BIOTECHNOLOGY RESEARCH AND : BRAIN - Investor Presentation
PU
09/15B R A I N BIOTECHNOLOGY RESEARCH AND : BRAIN AG Presents New Strategy at Capital..
PU
08/31B R A I N BIOTECHNOLOGY RESEARCH AND : Quarterly Statement as of 30 June 2020
PU
08/31B R A I N BIOTECHNOLOGY RESEARCH AND : Presentation of 9M Figures 2019/20
PU
08/31B.R.A.I.N. BIOTECHNOLOGY RESEARCH AN : BRAIN is pleased with its results for the..
EQ
08/31B R A I N BIOTECHNOLOGY RESEARCH AND : BRAIN is pleased with its results for the..
PU
08/12B R A I N BIOTECHNOLOGY RESEARCH AND : Hessian Minister for Digital Strategy and..
PU
07/23RECOVERING PLATINUM GROUP METALS : Heraeus and BRAIN successfully complete devel..
PU
07/07B R A I N BIOTECHNOLOGY RESEARCH AND : Change in the Management Board of BRAIN A..
PU
07/07B R A I N BIOTECHNOLOGY RESEARCH AND : Change in the Management Board of BRAIN A..
PU
More news
Financials
Sales 2020 41,3 M 48,0 M 48,0 M
Net income 2020 -8,40 M -9,78 M -9,78 M
Net Debt 2020 8,64 M 10,1 M 10,1 M
P/E ratio 2020 -17,0x
Yield 2020 -
Capitalization 147 M 171 M 171 M
EV / Sales 2020 3,78x
EV / Sales 2021 3,57x
Nbr of Employees 282
Free-Float 49,7%
Chart B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG
Duration : Period :
B.R.A.I.N. Biotechnology Research and Information Network AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 12,77 €
Last Close Price 7,42 €
Spread / Highest target 136%
Spread / Average Target 72,1%
Spread / Lowest Target 19,3%
EPS Revisions
Managers
NameTitle
Adriaan Moelker Chief Executive Officer
Georg Kellinghusen Chairman
Manfred Bender Chief Financial Officer
Anna Carina Eichhorn Member-Supervisory Board
Martin B. Jager Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG-31.30%171
ECOLAB INC.1.58%55 944
HENKEL AG & CO. KGAA-6.18%40 552
GIVAUDAN SA30.06%39 149
SIKA AG21.91%33 815
EMS-CHEMIE HOLDING AG30.71%20 940